Podcast: Lumen using spirulina to make ‘edible’ antibody drugs

Dan Stanton, Managing editor

July 25, 2022

We sit down with Lumen Biosciences CEO Brian Finrow to discuss how his company hopes to use its spirulina-based platform to develop drugs targeting gastrointestinal disorders.

Lumen Biosciences is a biotech looking to unlock the full potential of biologic drugs, whose promise has been held back by the lack of scalable technology.

The firm is developing ‘oral antibodies’ using its platform based on spirulina– the protein-rich cyanobacteria touted by many health enthusiasts as a ‘superfood’ – to create tiny factories that churn out therapeutic antibodies.


Image: Stock Photo Secrets

More details can be found in the text box below, but as part of the BioProcess International Theater at BIO in San Diego last month, I spoke with CEO and co-founder Brian Finrow.

Listen to the full interview as part of the Bioprocess Insider Expression Platform podcast here, on Apple, Amazon, Spotify, or wherever you get your podcasts.

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.

Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.

From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like